肌酸酐测量市场 - 预测 2024-2029

预计 2022 年肌酸酐测量市值为 2.9449 亿美元，预测期内复合年增长率为 9.38%。

肌酸酐测量是为了检查人体内肾臟的功能。残留在人体内的化合物称为肌酸酐。透过测量人体内的肌酸酐浓度可以判断肾臟的状况。肌酸酐水平可以从血液和尿液样本中测量。过滤后的肌酸酐会作为尿液中的过滤废物从体内排放。

肌酸酐测量市场的驱动因素

影响肌酸酐测量市场成长的主要因素是肾臟疾病和其他影响肾功能的慢性疾病的盛行率不断增加。实施适当的政府倡议和增加预防性医疗保健的采用也是推动肌酸酐测量市场的其他倡议。此外，老年人口的增加以及各种产品的开拓也是将进一步推动肌酸酐测量市场的因素。

肾臟相关疾病的盛行率增加

由于糖尿病和慢性肾臟病（CKD）盛行率的上升、人口老化以及研发力度的加大，全球肌酸酐测量市场预计在未来几年将成长。全球肌酸酐测量产业也受到外源标记成分的开发、政府融资的增加和临床实验室业务的增加的推动。血清肌酸酐检测在世界各地的临床化学实验室进行。市场供应商提供的有利报销政策和尖端设计，例如闭塞袖带和带有植入连接的泵，预计也将促进肌酸酐测量市场的成长。

增加照护现场肌酸酐测量设备的使用

照护现场肌酸酐测定仪用于透过筛检计画早期诊断慢性肾臟病。使用可携式设备进行肌酸酐照护现场分析可在居家医疗环境中提供快速诊断结果。这对于需要肾臟替代的末期肾功能衰竭病例也有益。透过 POC 进行居家肌酸酐检测，由于其简单和方便，可以进行更多的肾功能分析。

肌酸酐检测技术进展

我们使用单模光纤-多芯光纤-多模光纤-单模光纤（SMFMCF-MMF-SMF）构建了一种简单、便携式、高灵敏度的生物感测器，用于检测人体内的肌酸酐。使用化学蚀刻将感测器探头的直径减小至 90 m (EW)，从而能够产生强大的倏逝波。此感测器探针使用氧化石墨烯 (GO)、金奈米颗粒 (AuNP)、二硫化钼奈米颗粒 (MoS2-NP) 和肌酸酐酶 (CA) 进行功能化。使用光纤局域表面等离子体共振 (LSPR) 测量肌酸酐浓度。二维 (2D) 材料（GO 和 MoS2-NP）已用于增强生物相容性。此外，CA用于增加探针的特异性，EW用于提高AuNPs的LSPR效果。

对肌酸酐测量套件和试剂的需求不断增长

影响肾功能的各种慢性疾病的日益普及也增加了对肌酸酐测量套件和试剂的需求。例如，肾衰竭最常见的原因分别是糖尿病和高血压。全球易患肾臟疾病的老年人口不断增加、旨在促进肾臟健康的有利政府立法以及开拓的监测技术正在促进肌酸酐测量市场的成长。采用照护现场肌酸酐测量设备作为一种快速方法就是这样一个潜在的技术发展。

扩大酶法的采用

酵素法使用一种称为肌酸酐磷酸激酶 (CPK) 的酵素将肌酸酐转化为磷酸肌酸。然后使用磷酸肌酸测量来确定肌酸酐浓度。酵素法可用于血清、血浆和全血，并且比 Jaffe 的动力学方法更快。此外，观察到约 30 mg/dL 至 700 mg/dL 的线性动态范围。酵素法的主要缺点是容易受到尿液检体中过量胆红素、抗坏血酸和固色剂浓度的干扰。

血清肌酸酐预计将占据最大市场占有率

肾功能检查中最常用的检查项目之一是血清肌酸酐。它用于计算估计肾小球过滤率（eGFR），作为肾功能的指标。它是识别慢性肾臟疾病的绝佳指标。肾丝球滤过率（GFR）是肾功能的理想指标，与血中肌酸酐水平呈负相关。由于监测 GFR 非常耗时，因此通常使用考虑了血清肌酸酐 (sCr) 等内源性滤过指标的公式来估算 GFR。

血清肌酸酐检测的不断推出和进步、研发活动的扩大、知名公司采取重大战略倡议、慢性肾臟病率上升等正在推动肌酸酐测量市场的成长。

北美的胚胎着床前基因检测市场预计将稳定成长。

由于肾臟疾病盛行率上升、医疗基础设施发达、预防性医疗意识不断提高以及该地区对检测的接受程度等多种原因，预计肌酸酐测量市场将在预测期内增长。我是。例如，美国国家糖尿病、消化和肾臟疾病研究所估计，美国有 3700 万人（近七分之一）患有慢性肾臟病(CKD)。患有糖尿病和高血压（肾臟疾病的两个主要原因）的美国人患慢性肾病的可能性明显更高。

目录

第一章简介

• 市场概况
• 市场定义
• 调查范围
• 市场区隔
• 货币
• 先决条件
• 基准年和预测年时间表

第二章调查方法

• 调查资料
• 先决条件

第三章执行摘要

• 研究亮点

第四章市场动态

• 市场驱动因素
• 市场限制因素
• 波特五力分析
• 产业价值链分析

第五章肌酸酐测量市场：依类型

• 介绍
• 贾菲法
• 酵素法

第六章肌酸酐测量市场：依样本类型

• 介绍
• 血液/血清
• 尿

第 7 章 肌酸酐测量市场：依最终用户分类

• 介绍
• 医院
• 诊断实验室

第八章肌酸酐测量市场：按地区

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 其他的
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章竞争环境及分析

• 主要企业及策略分析
• 市场占有率分析
• 合併、收购、协议和合作
• 供应商竞争力矩阵

第十章 公司简介

• Mayo Clinic
• Ilex Medical
• Biogenix Inc. Pvt. Ltd.
• Nova Biomedical
• Sigma-Aldrich
• Cayman Chemical
• Biotec Co.
• Fresenius Kidney Care
• Fujifilm
• Healio

The creatinine measurement market was valued at US$294.49 million in 2022 and is expected to grow at a CAGR of 9.38% during the forecast period.

The creatinine measurement is performed to check the function of the kidney in the human body. The leftover chemical compound found in the human body is called creatinine. The status of the kidney can be figured out by measuring creatinine levels in the human body. The creatinine levels can be measured from blood samples and urine samples. After the process, the filtered-out creatinine exits the human body with urine as filtered waste.

Driving factors for the creatinine measurement market

The major factor influencing the growth of the creatinine measurement market is the growing prevalence of renal disorders and other chronic illnesses that affect renal function. Implementation of suitable government initiatives and increasing adoption of preventive healthcare are other initiatives that fuel the creatinine measurement market. Moreover, the increase in the geriatric population and various product developments are some other factors that further propel the creatinine measurement market.

Growing prevalence of kidney-related disease

The worldwide creatinine measurement market is anticipated to rise over the next years as a result of rising rates of diabetes and chronic kidney disease (CKD), an aging population, and increased R&D efforts. The global creatinine measurement industry is also being driven by the development of exogenous marker components, a rise in government financing, and an increase in clinical laboratory operations. Serum creatinine tests are carried out by clinical chemistry labs all over the world. Favourable reimbursement policies and cutting-edge designs created by market vendors, including occlusive cuffs or pumps with implant connections, are also anticipated to fuel this creatinine measurement market growth.

Increasing use of point-of-care creatinine instruments

Point-of-care creatinine instruments are used for early diagnosis of chronic kidney diseases throughout the screening programs. The use of portable devices for creatinine point-of-care analysis enables fast diagnostic results in homecare settings. This also proves to be beneficial for end-stage renal failure cases which require renal replacement. The use of home creatinine testing with POC leads to more renal function analysis owing to simplicity and convenience.

Technological advancement in the detection of creatinine

A straightforward, transportable, and sensitive biosensor is constructed using single-mode fiber-multicore fiber-multimode fiber-single mode fiber (SMFMCF-MMF-SMF) to detect creatinine in the human body. Chemical etching was used to shrink the sensing probe's diameter to 90 m (EWs), which allowed for the generation of powerful evanescent waves. The sensor probe is functionalized using graphene oxide (GO), gold nanoparticles (AuNPs), molybdenum disulfide nanoparticles (MoS2-NPs), and the enzyme creatininase (CA). Creatinine concentration is measured using fiber optic localized surface plasmon resonance (LSPR). To boost biocompatibility, two-dimensional (2D) materials (GO and MoS2-NPs) are used. CA is also used to increase probe specificity, while EWs are used to improve the LSPR effect of AuNPs.

Rising demand for creatinine measurement kits and reagents

A growth in the prevalence of various chronic diseases that affect renal function also adds to the need for creatinine measurement kits and reagents. For instance, the majority of all occurrences of renal failure are caused, respectively, by diabetes and high blood pressure. An increase in the elderly population worldwide, who are more susceptible to renal problems, favourable government laws designed to promote renal health, and the development of monitoring technology all contribute to the creatinine measurement market growth. Employing point-of-care creatinine measurement equipment as a quick way is one of these potential technical developments.

Growing adoption for enzymatic method

The enzymatic approach converts creatinine to phosphocreatine using the enzyme creatinine phosphokinase (CPK). The measurement of phosphocreatine is then utilized to determine the creatinine concentration. The enzymatic approach may be used in serum, plasma, or whole blood and is quicker than Jaffe's kinetic method. A linear dynamic range of around 30 mg/dL to 700 mg/dL is also seen. The primary drawbacks of the enzymatic approach are its susceptibility to interference with excessive bilirubin, ascorbic acid, and chromogen concentrations in urine samples.

Serum creatinine is anticipated to hold the maximum market share

One of the most used laboratory tests for renal function is serum creatinine. As a measure of kidney function, it is used to calculate the estimated glomerular filtration rate (eGFR). It serves as an excellent indication for identifying chronic renal disorders. The ideal indicator of kidney function, the glomerular filtration rate (GFR), is negatively correlated with the blood creatinine content. GFR is often approximated using equations that take into account endogenous filtration indicators such as serum creatinine (sCr) due to the time-consuming nature of monitoring GFR.

Growing launches and advancements in serum creatinine tests, expanding R&D activity, prominent companies adopting important strategic initiatives, and rising prevalence of chronic renal disease are all driving creatinine measurement market growth.

In North America, it is projected that the preimplantation genetic testing market will grow steadily.

The creatinine measurement market is anticipated to grow during the projected period due to several reasons, including the rising incidence of renal illnesses, the presence of a well-developed healthcare infrastructure, the rising awareness of preventive healthcare, and the acceptance of testing in the area. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases estimates that 37 million individuals in the United States, or almost one-seventh of the population, are affected by chronic kidney disease (CKD). Americans who have diabetes or high blood pressure, the two most common causes of renal disease, are considerably more likely to develop CKD.

Market Key Developments

• In July 2022, Creative Enzymes, one of the top manufacturers of diagnostic enzymes, introduced new enzymes for the manufacture of creatinine test kits.
• In March 2022, The Nova Max Pro Creatinine/eGFR Metre System is now available in all countries that are members of the European Economic Area. Nova Max Pro is a significant new tool for improving renal care through early kidney disease identification and kidney function assessment outside of the hospital.

Segmentation:

By Type

• Jaffe's Kinetic Method
• Enzymatic Method

By Sample Type

• Blood/Serum
• Urine

By End-User

• Hospitals
• Diagnostic Laboratories

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. CREATININE MEASUREMENT MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Jaffe's Kinetic Method
• 5.3. Enzymatic Method

6. CREATININE MEASUREMENT MARKET, BY SAMPLE TYPE

• 6.1. Introduction
• 6.2. Blood/Serum
• 6.3. Urine

7. CREATININE MEASUREMENT MARKET, BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Diagnostic Laboratories

8. CREATININE MEASUREMENT MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Mayo Clinic
• 10.2. Ilex Medical
• 10.3. Biogenix Inc. Pvt. Ltd.
• 10.4. Nova Biomedical
• 10.5. Sigma-Aldrich
• 10.6. Cayman Chemical
• 10.7. Biotec Co.
• 10.8. Fresenius Kidney Care
• 10.9. Fujifilm
• 10.10. Healio